This mechanism of resistance derives from the persistent stimulation of the EGFR/RAS/RAF/ERK/MEK pathway when KRAS is mutated, regardless of the mutational status of EGFR. The KRAS testing is usually performed on tumor tissue, rather than from secondary lesions in case of metastatic disease. This evidence concerns the gene EGFR and neoplasm.